289 related articles for article (PubMed ID: 35588562)
1. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; Falip M; Sánchez-Carpintero R; Abad-Sazatornil MR; Poveda JL; Aibar JÁ; Cardenal-Muñoz E; Aras LM; Sánchez R; Sancho-López A; Trillo-Mata JL; Torrejón M; Gil A
Epilepsy Behav; 2022 Jul; 132():108711. PubMed ID: 35588562
[TBL] [Abstract][Full Text] [Related]
2. Value contribution of cenobamate for the treatment of Focal-Onset Seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through reflective Multi-Criteria Decision Analysis (MCDA).
Falip M; López González FJ; Martín-Herranz I; Merino-Bohórquez V; Montoya J; Rey Gómez-Serranillos I; Rodriguez Uranga JJ; Ruiz E; Sancho-López A; Trillo Mata JL; Antoni Vallès J; Álvarez-Barón E; Sabaniego J; Subías-Labazuy S; Gil A
Epilepsy Behav; 2023 Aug; 145():109350. PubMed ID: 37480633
[TBL] [Abstract][Full Text] [Related]
3. Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA).
Villanueva V; Carreño M; Gil-Nagel A; Serrano-Castro PJ; Serratosa JM; Toledo M; Álvarez-Barón E; Gil A; Subías-Labazuy S
Epilepsy Behav; 2021 Sep; 122():108222. PubMed ID: 34371462
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Lattanzi S; Trinka E; Russo E; Del Giovane C; Matricardi S; Meletti S; Striano P; Damavandi PT; Silvestrini M; Brigo F
Drugs; 2023 Oct; 83(15):1409-1424. PubMed ID: 37695433
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.
Guerrini R; Chiron C; Vandame D; Linley W; Toward T
Epilepsia Open; 2024 Apr; 9(2):689-703. PubMed ID: 38427284
[TBL] [Abstract][Full Text] [Related]
6. Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome: An indirect treatment comparison.
Devi N; Madaan P; Asrar MM; Sahu JK; Bansal D
Seizure; 2021 Oct; 91():316-324. PubMed ID: 34274891
[TBL] [Abstract][Full Text] [Related]
7. Treatment-Refractory Dravet Syndrome: Considerations for Novel Medications.
Lopez JC; Pare JR; Blackmer AB; Orth LE
J Pediatr Health Care; 2022; 36(5):479-488. PubMed ID: 35987555
[TBL] [Abstract][Full Text] [Related]
8. A critical evaluation of fenfluramine hydrochloride for the treatment of Dravet syndrome.
Schoonjans AS; Ceulemans B
Expert Rev Neurother; 2022 May; 22(5):351-364. PubMed ID: 33455486
[TBL] [Abstract][Full Text] [Related]
9. A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication.
Strzelczyk A; Schubert-Bast S
CNS Drugs; 2022 Mar; 36(3):217-237. PubMed ID: 35156171
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of fenfluramine in patients with Dravet syndrome: A systematic review and meta-analysis.
Sharawat IK; Panda PK; Kasinathan A; Panda P; Dawman L; Joshi K
Seizure; 2021 Feb; 85():119-126. PubMed ID: 33461030
[TBL] [Abstract][Full Text] [Related]
11. Fenfluramine significantly reduces day-to-day seizure burden by increasing number of seizure-free days and time between seizures in patients with Dravet syndrome: A time-to-event analysis.
Sullivan J; Specchio N; Devinsky O; Auvin S; Perry MS; Strzelczyk A; Gil-Nagel A; Dai D; Galer BS; Gammaitoni AR
Epilepsia; 2022 Jan; 63(1):130-138. PubMed ID: 34676542
[TBL] [Abstract][Full Text] [Related]
12. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
Nabbout R; Mistry A; Zuberi S; Villeneuve N; Gil-Nagel A; Sanchez-Carpintero R; Stephani U; Laux L; Wirrell E; Knupp K; Chiron C; Farfel G; Galer BS; Morrison G; Lock M; Agarwal A; Auvin S;
JAMA Neurol; 2020 Mar; 77(3):300-308. PubMed ID: 31790543
[TBL] [Abstract][Full Text] [Related]
13. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients.
Schoonjans A; Paelinck BP; Marchau F; Gunning B; Gammaitoni A; Galer BS; Lagae L; Ceulemans B
Eur J Neurol; 2017 Feb; 24(2):309-314. PubMed ID: 27790834
[TBL] [Abstract][Full Text] [Related]
14. Stiripentol for the treatment of seizures in Dravet syndrome.
Eschbach K; Knupp KG
Expert Rev Clin Pharmacol; 2019 May; 12(5):379-388. PubMed ID: 31017478
[TBL] [Abstract][Full Text] [Related]
15. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome.
Bishop KI; Isquith PK; Gioia GA; Gammaitoni AR; Farfel G; Galer BS; Nabbout R; Wirrell EC; Polster T; Sullivan J
Epilepsy Behav; 2021 Aug; 121(Pt A):108024. PubMed ID: 34023810
[TBL] [Abstract][Full Text] [Related]
16. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial.
Lagae L; Sullivan J; Knupp K; Laux L; Polster T; Nikanorova M; Devinsky O; Cross JH; Guerrini R; Talwar D; Miller I; Farfel G; Galer BS; Gammaitoni A; Mistry A; Morrison G; Lock M; Agarwal A; Lai WW; Ceulemans B;
Lancet; 2019 Dec; 394(10216):2243-2254. PubMed ID: 31862249
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: Compassionate use program in Germany.
Strzelczyk A; Pringsheim M; Mayer T; Polster T; Klotz KA; Muhle H; Alber M; Trollmann R; Spors H; Kluger G; Kurlemann G; Schubert-Bast S
Epilepsia; 2021 Oct; 62(10):2518-2527. PubMed ID: 34378197
[TBL] [Abstract][Full Text] [Related]
18. Fenfluramine for treatment-resistant epilepsy in Dravet syndrome and other genetically mediated epilepsies.
Sullivan J; Simmons R
Drugs Today (Barc); 2021 Jul; 57(7):449-454. PubMed ID: 34268532
[TBL] [Abstract][Full Text] [Related]
19. Failure to use new breakthrough treatments for epilepsy.
Klein P; Krauss GL; Steinhoff BJ; Devinsky O; Sperling MR
Epilepsia; 2023 Jun; 64(6):1458-1465. PubMed ID: 36855241
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of fenfluramine in patients with Dravet syndrome: A meta-analysis.
Zhang L; Li W; Wang C
Acta Neurol Scand; 2021 Apr; 143(4):339-348. PubMed ID: 33336426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
